Cargando…
Anti-Tumor Effects of Low Dose Zoledronate on Lung Cancer-Induced Spine Metastasis
Zoledronate (Zol) is an anti-resorptive/tumoral agent used for the treatment of many cancers including spinal bone metastasis. High systemic administration of a single dose is now the standard clinical care, yet it has been associated with several side effects. Here, we aimed to evaluate the effects...
Autores principales: | Akoury, Elie, Ramirez Garcia Luna, Ana Sofia, Ahangar, Pouyan, Gao, Xiaoya, Zolotarov, Pylyp, Weber, Michael H., Rosenzweig, Derek H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6722631/ https://www.ncbi.nlm.nih.gov/pubmed/31416169 http://dx.doi.org/10.3390/jcm8081212 |
Ejemplares similares
-
Low-dose zoledronate for the treatment of bone metastasis secondary to prostate cancer
por: Akoury, Elie, et al.
Publicado: (2019) -
Nanoporous 3D-Printed Scaffolds for Local Doxorubicin Delivery in Bone Metastases Secondary to Prostate Cancer
por: Ahangar, Pouyan, et al.
Publicado: (2018) -
Management of bone metastasis with zoledronic acid: A systematic review and Bayesian network meta-analysis
por: Lorange, Justin-Pierre, et al.
Publicado: (2023) -
Intra-tumor delivery of zoledronate mitigates metastasis-induced osteolysis superior to systemic administration
por: Nooh, Anas, et al.
Publicado: (2017) -
Zoledronic Acid Versus Denosumab for Prevention of Spinal Cord Compression in Advanced Cancers With Spine Metastasis: A Meta-Analysis of Randomized Controlled Trials
por: Al Farii, Humaid, et al.
Publicado: (2019)